A Closer Look at 5 Analyst Recommendations For OptimizeRx
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for OptimizeRx (NASDAQ:OPRX) over the past quarter, with a recent average 12-month price target of $14.4, down 4% from the prior average. Key analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. OptimizeRx has shown a positive revenue trend with a 51.43% growth rate, but faces challenges with a net margin of -35.04%.
August 12, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
OptimizeRx has received mixed analyst ratings with a recent average price target of $14.4, down 4% from the prior average. The company has shown a positive revenue trend but faces challenges with a net margin of -35.04%.
The mixed analyst ratings and the slight decline in the average price target suggest a neutral short-term impact on the stock. The positive revenue trend is a good sign, but the challenges with the net margin balance out the overall sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100